



Recent Scientific Advances in Vaccine Platforms

Guest Editors:

Prof. Dr. Pan Tao

College of Veterinary Medicine,
Huazhong Agricultural University,
Wuhan, China

Dr. Jingen Zhu

Department of Biology, Catholic
University of America,
Washington, DC, USA

Deadline for manuscript
submissions:

closed (30 September 2024)

Message from the Guest Editors

Vaccines are recognized as the most cost-effective means of preventing the spread of infectious diseases. However, the constant evolution of pathogens and the emergence of new infectious agents pose significant challenges to vaccine development. Due to the emergence of innovative vaccine platforms, vaccine development has made significant progress in recent years. This Special Issue of the journal *Vaccines* aims to showcase recent breakthroughs in vaccine platforms. This collection will include articles exploring various vaccine platforms, such as mRNA-based vaccines, viral vector vaccines, nanomaterial vaccines, antigen delivery systems, novel adjuvants, etc. Key areas of focus will include the latest discoveries in the development of novel vaccine platforms, the optimization of current vaccine platforms and exploration of their mechanisms, and the application of vaccine platforms to improve vaccine efficacy and safety. Articles that explore the platforms' roles at all stages of vaccine development, such as antigen identification, vaccine formulation, vaccine production, and vaccination, are welcome for submission.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)